Please login to the form below
Highly Specialised Technology
This page shows the latest Highly Specialised Technology news and features for those working in and with pharma, biotech and healthcare.
NICE approves BioMarin’s Brineura after initial setback
The positive recommendation of Brineura was agreed by NICE’s Highly Specialised Technology committee. ... Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE.
Latest news
-
Spinraza managed access deal in England breaks deadlock for Biogen
a prevalence to go through NICE's highly specialised technology (HST) route, which is reserved for the rarest orphan and ultra-orphan treatments. ... Patient groups say the health economics of a rare disease like SMA make it highly unlikely to be passed
-
NICE knocks back BioMarin’s Batten disease drug
The decision, which was published under NICE’s Highly Specialised Technology (HST) committee, marks the end of a year-long negotiation between BioMarin and NHS England. ... Once these elements are excluded, the cost-effectiveness estimates for
-
‘Inflexible’ NICE blocking access to rare disease drugs
NICE has a Highly Specialised Technology (HST) appraisal, which has seen a number of innovative pricing and reimbursement deals done with companies to bring orphan and ultra-orphan drugs to NHS ... patients. However many rare diseases do not qualify for
-
NICE appraisal fees to be introduced despite opposition
The fee for single technology appraisals (STAs) and highly specialised technology appraisals (HTAs) will be £126, 000 ($158, 500, 140, 400).
-
Promising more appraisal capacity, NICE revives industry fee idea
NICE is proposing that bigger companies pay £126, 000 ($160, 000) for a single technology appraisal or a highly specialised technology appraisal (for rare disease drugs), or £94, 500 for smaller ... Industry association the ABPI hasn’t yet responded
Spinraza managed access deal in England breaks deadlock for Biogen
NICE knocks back BioMarin’s Batten disease drug
NICE appraisal fees to be introduced despite opposition
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Assessing the impact of disease prevalence on access and pricing of rare disease drugs in England
This is especially the case in markets using cost-effectiveness analysis (CEA) for their health technology assessments (HTA). ... focus on the single technology appraisal [STA] and the highly specialised technology [HST] frameworks), or, second, via NHS
-
Evolution or revolution: the latest review of NICE methods
The 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) included a commitment from NICE to scope and initiate a review of the methods for its Technology Appraisal Programme (TAP) ... A broad range of technologies. NICE has said that the
-
#OrkambiNow?
The row boiled over into accusations being traded publicly – Vertex calling the health service budget holder’s stance ‘outrageous’ last summer and NHS England’s head of specialised medicines commissioning John ... The STA system doesn’t
-
Rare diseases: meeting the challenge
NICE, which has its own Highly Specialised Technology (HST) assessment process, has come under fire for the change in April 2017 to the way it assesses therapies to treat the rarest
Assessing the impact of disease prevalence on access and pricing of rare disease drugs in England
Evolution or revolution: the latest review of NICE methods
#OrkambiNow?
Rare diseases: meeting the challenge
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
No results were found
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
